These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 16806016)
41. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells. Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918 [TBL] [Abstract][Full Text] [Related]
42. Expression of single-chain Fv gene specific for gamma-seminoprotein by RTS and its biological activity identification. Han Y; Haun Y; Deng J; Gao F; Pan B; Cui D Biotechnol Prog; 2006; 22(4):1084-9. PubMed ID: 16889383 [TBL] [Abstract][Full Text] [Related]
43. SEA-scFv as a bifunctional antibody: construction of a bacterial expression system and its functional analysis. Sakurai N; Kudo T; Suzuki M; Tsumoto K; Takemura S; Kodama H; Ebara S; Teramae A; Katayose Y; Shinoda M; Kurokawa T; Hinoda Y; Imai K; Matsuno S; Kumagai I Biochem Biophys Res Commun; 1999 Mar; 256(1):223-30. PubMed ID: 10066451 [TBL] [Abstract][Full Text] [Related]
44. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837 [TBL] [Abstract][Full Text] [Related]
45. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2. Biburger M; Weth R; Wels WS J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482 [TBL] [Abstract][Full Text] [Related]
46. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. Gruber M; Schodin BA; Wilson ER; Kranz DM J Immunol; 1994 Jun; 152(11):5368-74. PubMed ID: 8189055 [TBL] [Abstract][Full Text] [Related]
47. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody. Gao Y; Xiong D; Yang M; Liu H; Peng H; Shao X; Xu Y; Xu C; Fan D; Qin L; Yang C; Zhu Z Leukemia; 2004 Mar; 18(3):513-20. PubMed ID: 14981526 [TBL] [Abstract][Full Text] [Related]
48. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway. Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794 [TBL] [Abstract][Full Text] [Related]
49. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154 [TBL] [Abstract][Full Text] [Related]
50. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. Shen J; Vil MD; Jimenez X; Zhang H; Iacolina M; Mangalampalli V; Balderes P; Ludwig DL; Zhu Z J Immunol Methods; 2007 Jan; 318(1-2):65-74. PubMed ID: 17126853 [TBL] [Abstract][Full Text] [Related]
51. Redirection of T cell-mediated cytotoxicity by a recombinant single-chain Fv molecule. George AJ; Titus JA; Jost CR; Kurucz I; Perez P; Andrew SM; Nicholls PJ; Huston JS; Segal DM J Immunol; 1994 Feb; 152(4):1802-11. PubMed ID: 8120389 [TBL] [Abstract][Full Text] [Related]
52. [Construction and expression of disulphide stabilized anti-CD3/anti-Pgp diabody]. Su Y; Liu J; Gao Y; Qin L; Yang M; Wang J; Xu Y; Shao X; Ji Q; Xiong D; Yang C Sheng Wu Gong Cheng Xue Bao; 2009 Jul; 25(7):1042-8. PubMed ID: 19835146 [TBL] [Abstract][Full Text] [Related]
53. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody. Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528 [TBL] [Abstract][Full Text] [Related]
54. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Kuo SR; Wong L; Liu JS Protein Eng Des Sel; 2012 Oct; 25(10):561-9. PubMed ID: 22740616 [TBL] [Abstract][Full Text] [Related]
55. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971 [TBL] [Abstract][Full Text] [Related]
56. [Cloning of the variable region genes from hybridoma against bFGF and expression of single chain antibody fragments in E.coli HB2151]. Wang H; Chen D; Deng N; Xiang JJ; Jin YJ; Huang HL; Tang Y; Yang HY Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Dec; 23(12):1150-3. PubMed ID: 18062890 [TBL] [Abstract][Full Text] [Related]
57. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703 [TBL] [Abstract][Full Text] [Related]
58. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975 [TBL] [Abstract][Full Text] [Related]
59. A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells. Song LP; Cheng JL; Wang XB; Zhang Z; Fang M; Zhou ZY; Huang HL Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jun; 35(6):503-10. PubMed ID: 12796809 [TBL] [Abstract][Full Text] [Related]
60. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]